SI1487444T1 - Uporaba piridil-amidov kot inhibitorjev angiogeneze - Google Patents
Uporaba piridil-amidov kot inhibitorjev angiogenezeInfo
- Publication number
- SI1487444T1 SI1487444T1 SI200331755T SI200331755T SI1487444T1 SI 1487444 T1 SI1487444 T1 SI 1487444T1 SI 200331755 T SI200331755 T SI 200331755T SI 200331755 T SI200331755 T SI 200331755T SI 1487444 T1 SI1487444 T1 SI 1487444T1
- Authority
- SI
- Slovenia
- Prior art keywords
- angiogenesis
- inhibitors
- pyridyl amides
- pyridyl
- amides
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- -1 pyridyl amides Chemical class 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02006697A EP1348434A1 (en) | 2002-03-27 | 2002-03-27 | Use of pyridyl amides as inhibitors of angiogenesis |
| PCT/EP2003/003060 WO2003080054A1 (en) | 2002-03-27 | 2003-03-24 | Use of pyridyl amides as inhibitors of angiogenesis |
| EP03744849A EP1487444B9 (en) | 2002-03-27 | 2003-03-24 | Use of pyridyl amides as inhibitors of angiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1487444T1 true SI1487444T1 (sl) | 2010-04-30 |
Family
ID=27798796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200331755T SI1487444T1 (sl) | 2002-03-27 | 2003-03-24 | Uporaba piridil-amidov kot inhibitorjev angiogeneze |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060052419A1 (https=) |
| EP (2) | EP1348434A1 (https=) |
| JP (1) | JP4599062B2 (https=) |
| AT (1) | ATE453393T1 (https=) |
| AU (1) | AU2003215672A1 (https=) |
| CY (1) | CY1109925T1 (https=) |
| DE (1) | DE60330757D1 (https=) |
| DK (1) | DK1487444T3 (https=) |
| ES (1) | ES2337780T3 (https=) |
| PT (1) | PT1487444E (https=) |
| SI (1) | SI1487444T1 (https=) |
| WO (1) | WO2003080054A1 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| MXPA06010543A (es) | 2004-03-15 | 2007-03-26 | Ptc Therapeutics Inc | Derivados de carbolina utiles en la inhibicion de la angiogenesis. |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| JP4855485B2 (ja) * | 2006-02-17 | 2012-01-18 | エフ．ホフマン−ラ ロシュ アーゲー | ５ｈｔ２／ｄ３モジュレーターとしてのベンゾイル−ピペリジン誘導体 |
| WO2008026018A1 (en) * | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| MX2009004615A (es) | 2006-10-31 | 2009-05-22 | Hoffmann La Roche | Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3). |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| RU2529468C2 (ru) | 2008-06-24 | 2014-09-27 | Топотаргет А/С | Производные 1, 2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида |
| JP5688367B2 (ja) | 2008-08-29 | 2015-03-25 | トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔ Ａ／Ｓ | 新規なウレアおよびチオウレア誘導体 |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| JP6038792B2 (ja) | 2010-09-03 | 2016-12-07 | フォーマ ティーエム， エルエルシー． | 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体 |
| PE20140011A1 (es) | 2010-09-03 | 2014-01-31 | Forma Tm Llc | Compuestos y composiciones novedosos para la inhibicion de nampt |
| CN106243023A (zh) | 2010-09-03 | 2016-12-21 | 福马Tm有限责任公司 | 用于抑制nampt的胍化合物和组合物 |
| EP2640704A1 (en) | 2010-11-15 | 2013-09-25 | Abbvie Inc. | Nampt inhibitors |
| AU2011329233A1 (en) | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| RU2017112522A (ru) | 2011-05-04 | 2019-01-24 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| WO2012154194A1 (en) | 2011-05-09 | 2012-11-15 | Forma Tm, Llc | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt) |
| US8975398B2 (en) | 2012-05-11 | 2015-03-10 | Abbvie Inc. | NAMPT inhibitors |
| AR091022A1 (es) | 2012-05-11 | 2014-12-30 | Abbvie Inc | Inhibidores del nampt |
| CA2873075A1 (en) | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Nampt inhibitors |
| MX2014013758A (es) | 2012-05-11 | 2015-02-05 | Abbvie Inc | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. |
| WO2014085607A1 (en) | 2012-11-29 | 2014-06-05 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| JP6473133B2 (ja) * | 2013-03-15 | 2019-02-20 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの共有結合性阻害剤 |
| EP3016946B1 (en) | 2013-07-03 | 2022-10-12 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| HK1255438A1 (zh) | 2015-08-18 | 2019-08-16 | 卡尔约药物治疗公司 | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| KR102831570B1 (ko) | 2018-05-04 | 2025-07-10 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| MX2021000887A (es) | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| CN109776494B (zh) * | 2018-12-25 | 2021-06-18 | 中国人民解放军第二军医大学 | 一种多靶点抗肿瘤活性的烟酰胺磷酸核糖转移酶氮芥类抑制剂及其制备与应用 |
| US20210339449A1 (en) | 2019-01-16 | 2021-11-04 | Toray Industries, Inc. | Polyolefin multilayer microporous film and production method therefor |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| JP2024518089A (ja) | 2021-05-13 | 2024-04-24 | リメディー プラン，インコーポレーテッド | Ｎａｍｐｔ阻害剤とその使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224326A (en) * | 1978-09-21 | 1980-09-23 | Eli Lilly And Company | Immunosuppressive agents |
| US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) * | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19624704A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
| WO1998002170A1 (en) * | 1996-07-17 | 1998-01-22 | The General Hospital Corporation | Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene |
| DE19756235A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
| DE19756236A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19756212A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19756261A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
| DE19818044A1 (de) * | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
-
2002
- 2002-03-27 EP EP02006697A patent/EP1348434A1/en not_active Withdrawn
-
2003
- 2003-03-24 DE DE60330757T patent/DE60330757D1/de not_active Expired - Lifetime
- 2003-03-24 WO PCT/EP2003/003060 patent/WO2003080054A1/en not_active Ceased
- 2003-03-24 AU AU2003215672A patent/AU2003215672A1/en not_active Abandoned
- 2003-03-24 SI SI200331755T patent/SI1487444T1/sl unknown
- 2003-03-24 ES ES03744849T patent/ES2337780T3/es not_active Expired - Lifetime
- 2003-03-24 JP JP2003577882A patent/JP4599062B2/ja not_active Expired - Fee Related
- 2003-03-24 EP EP03744849A patent/EP1487444B9/en not_active Expired - Lifetime
- 2003-03-24 US US10/509,362 patent/US20060052419A1/en not_active Abandoned
- 2003-03-24 DK DK03744849.5T patent/DK1487444T3/da active
- 2003-03-24 AT AT03744849T patent/ATE453393T1/de active
- 2003-03-24 PT PT03744849T patent/PT1487444E/pt unknown
-
2010
- 2010-03-22 CY CY20101100264T patent/CY1109925T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1109925T1 (el) | 2014-09-10 |
| EP1487444B1 (en) | 2009-12-30 |
| EP1487444A1 (en) | 2004-12-22 |
| DK1487444T3 (da) | 2010-04-12 |
| US20060052419A1 (en) | 2006-03-09 |
| EP1348434A1 (en) | 2003-10-01 |
| PT1487444E (pt) | 2010-02-11 |
| ATE453393T1 (de) | 2010-01-15 |
| DE60330757D1 (de) | 2010-02-11 |
| EP1487444B9 (en) | 2010-07-21 |
| JP2005528361A (ja) | 2005-09-22 |
| ES2337780T3 (es) | 2010-04-29 |
| AU2003215672A1 (en) | 2003-10-08 |
| JP4599062B2 (ja) | 2010-12-15 |
| WO2003080054A1 (en) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1487444T1 (sl) | Uporaba piridil-amidov kot inhibitorjev angiogeneze | |
| MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
| IL196543A (en) | Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders | |
| DE602004008895D1 (en) | Dpp-iv-hemmer | |
| PL369108A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| JO2372B1 (en) | Source drugs of 4-phenylpyridine derivatives | |
| MY147780A (en) | Carboxamide compounds and their use as calpain inhibitors | |
| WO2004005279A3 (en) | Substituted anthranilic amide derivatives and methods of use | |
| ATE440603T1 (de) | 8-hydroxychinolinderivate | |
| CY1112024T1 (el) | Αναστολεις υποδοχεων adp αιμοπεταλιων | |
| TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| DE60003863D1 (de) | Dioxocyclopentylhydroxamsäure | |
| MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
| WO2005005389A3 (en) | Malonamide derivatives | |
| WO2004022528A3 (en) | Arylglycine derivatives and their use as glycine transport inhibitors | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| TW200700391A (en) | Pyridine-2-carboxamide derivatives as mglur5 antagonists | |
| JO2298B1 (en) | 2- (5.3 Pace-Tri-Fluoromethyl) -N-Methyl-N-_-6-Morpholine-4-YL-4-and-Tolyl-Pyridine-3-YL) | |
| MXPA05010020A (es) | Derivados de oxamida. | |
| MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
| MY141233A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
| IL161842A (en) | 2-amino-4-heteroarylethyl-thiazoline derivatives and pharmaceutical compositions comprising them | |
| GB0407025D0 (en) | Novel compounds | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents |